Home » Uncategorized (Page 202)
Category Archives: Uncategorized
Lycopene: reducing the risk of cancer and cardiovascular disease, effect on the eye and bone health or hepatoprotective properties
![]()
Lycopene is a natural carotenoid occurring in tomatoes and many other non-animal sources including fruits, vegetables and microorganisms. Lycopene has been shown to provide many health benefits such as reducing the risk of cancer and cardiovascular disease, effect on the eye and bone health or hepatoprotective properties. These health benefits together with its red color make it an attractive ingredient for functional foods.
In foods, lycopene can be successfully delivered in the form of oil-in-water emulsions, but in order to preserve its unique antioxidant properties, it has to be protected from premature oxidation.
read at
http://www.chemistryviews.org/details/news/1070983/Lycopene_Preventing_Degradation.html
- Effect of different antioxidants on lycopene degradation in oil-in-water emulsions,
Ricard Bou, Caitlin Boon, Asiamah Kweku, Diana Hidalgo, Eric A. Decker,
Eur. J. Lipid Sci. Technol. 2011, 113.
DOI: 10.1002/ejlt.201000524
Stem Cell Research – encouraging results – caustiously optimistic
Two HIV-positive patients in the United States who underwent bone marrow transplants for cancer have stopped anti-retroviral therapy and still show no detectable sign of the HIV virus, researchers said Wednesday.
The first person reported to be cured of HIV, American Timothy Ray Brown, underwent a stem cell transplant in 2007 to treat his leukemia. He was reported by his German doctors to have been cured of HIV two years later.
The researchers, Timothy Henrich and Daniel Kuritzkes of the Harvard-affiliated Brigham and Women’s Hospital in Boston, announced last year that blood samples taken from the men — who both had blood cancers — showed no traces of the HIV virus eight months after they received bone marrow transplants to replace cancerous blood cells with healthy donor cells.
“These findings clearly provide important new information that might well alter the current thinking about HIV and gene therapy,” Kevin
View original post 57 more words
Novartis’ eye drug Lucentis gains fourth indication approval in Europe
July 5 2013 | By Márcio Barra

In a press release launched today, Novartis announced that the EU has approved Lucentis (Ranibizumab) as the first effective treatment of sight problems caused by choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).
View original post 333 more words
FDA approves Orexo’s Zubsolv for people suffering from opioid dependence
U.S. Food and Drug Administration (FDA) has approved Zubsolv™ (buprenorphine/naloxone) sublingual tablet CIII. Zubsolv is indicated for use as maintenance treatment for people suffering from opioid dependence and should be used as part of a complete treatment plan to include counselling and psychosocial support. Zubsolv is a once-daily, sublingual tablet with an advanced formulation of buprenorphine and naloxone that fully dissolves within minutes. Compared with other buprenorphine/naloxone treatments, Zubsolv has higher bioavailability, faster dissolve time, and smaller tablet size with a new menthol taste. Zubsolv will be launched in September by our subsidiary in the United States, Orexo US, Inc and our partner Publicis Touchpoint Solutions…
FDA approves Orexo’s Zubsolv for people suffering from opioid dependence.
Anthrax Killer from the Sea
Anthrax Killer from the Sea
Unusual antibiotic from a marine actinomycete is effective against anthrax
http://www.chemistryviews.org/details/ezine/4972631/Anthrax_Killer_from_the_Sea.html
- Anthracimycin, a Potent Anthrax Antibiotic from a Marine-Derived Actinomycete,
Kyoung Hwa Jang, Sang-Jip Nam, Jeffrey B. Locke, Christopher A. Kauffman, Deanna S. Beatty, Lauren A. Paul, William Fenical,
Angew. Chem. Int. Ed. 2013.
DOI: 10.1002/anie.201302749
Sandoz launches generic metronidazole in the US
Sandoz has launched metronidazole 1% topical gel, the first generic version of METROGEL® 1%.
read all at
Cancer treatment using the nanofiber mesh with self-heating/anticancer drug release functions
A research team headed by Dr. Mitsuhiro Ebara, a MANA Scientist of the Biomaterials Unit of the International Center for Materials Nanoarchitectonics (WPI-MANA, NIMS) developed a new nanofiber mesh which is capable of simultaneously realizing thermotherapy (hyperthermia) and chemotherapy (treatment with anticancer drugs) of tumors.
Using this nanofiber mesh, the team succeeded in efficiently inducing natural death (apoptosis) of epithelial cancer cells.
Flamel Technologies Announces FDA Approval of Bloxiverz

LYON, FRANCE — (Marketwire) — 06/03/2013 — Flamel Technologies today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for Bloxiverz (neostigmine methylsulfate), a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Flamel expects to launch Bloxiverz in July 2013 in 0.5 and 1.0 mg/mL strengths
read all at
.http://www.drugs.com/newdrugs/flamel-technologies-announces-fda-approval-bloxiverz-3802.html
Sunovion Pharmaceuticals Inc. Announces FDA Approval of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression
![]()
lurasidone
MARLBOROUGH, Mass. – Monday, July 1st 2013 [ME NewsWire]
First Atypical Antipsychotic Indicated for the Treatment of Major Depressive Episodes Associated with Bipolar I Disorder (Bipolar Depression) Both as Monotherapy and as Adjunctive Therapy with Either Lithium or Valproate
(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for the use of Latuda® (lurasidone HCl) as 1) monotherapy and 2) adjunctive therapy with either lithium or valproate, both to treat adult patients with major depressive episodes associated with bipolar I disorder (bipolar depression).
read all at
http://www.me-newswire.net/news/7829/en
Lurasidone (trade name Latuda) is an atypical antipsychotic developed by Dainippon Sumitomo Pharma and marketed by Sunovion in the USA. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 28, 2010 after a review that found that two of the four Phase III clinical trials supported efficacy, while one showed only marginal efficacy and one was not interpretable because of high drop-out rates. It is currently pending approval for the treatment of bipolar disorder in the United States. It was launched in Canada for the treatment of schizophrenia in September 2012, Health Canada giving their Summary Basis of Decision (SBD) as favourable on October 15, 2012
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....











